Stratec stock trades at EUR 22.23 after plus 0.14 percent

Published on 09/30/2026 at 10:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stratec stock was at EUR 22.23, plus 0.14 percent versus EUR 22.20 on September 30, 2026. Q2 revenue rose 2.4 percent year over year.

Techniker montieren automatisiertes Diagnostik-Analysegerät in modernem Reinraum — Stratec SE (DE000STRA555) fertigt automatisierte Analysesysteme, hier ein Reinraum mit Laborrobotik im Einsatz, Illustration mit AI erstellt.

Stratec (ISIN DE000STRA555) was trading at EUR 22.23 at Lang & Schwarz on September 30, 2026, plus 0.14 percent versus the EUR 22.20 prior close. The Q2 recovery is measurable, but the second half still carries the central execution test.

Q2 margin shows a recovery

Stratec reported a 2.4 percent year-over-year increase in currency-adjusted Q2 2026 revenue and an adjusted EBIT margin of 11.9 percent, according to Finanznachrichten on September 17, 2026. The margin improvement contrasts with the weak first quarter and gives the recovery a clearer operating basis.

A separate review of the August half-year report put the adjusted EBIT margin at 11.9 percent in Q2 2026, versus 5.4 percent in the prior-year quarter, while adjusted EBIT reached EUR 7.0 million, according to Börse Global on August 31, 2026.

Analyst downgrade raises the bar

The improvement has not removed the delivery risk. Finanznachrichten reported that mwb research downgraded Stratec from Hold to Sell on September 17, 2026, while retaining a EUR 21.00 price target.

mwb research calculated that Stratec would need second-half revenue of EUR 149.0 million to EUR 161.0 million to meet its 2026 outlook, equivalent to 12.0 percent to 22.0 percent growth against the second half of 2025. That comparison makes customer ordering and the consumables business the key variables for the rest of the year.

Stratec stock stays below yearly range high

Stratec stock was trading at EUR 22.23 at Lang & Schwarz at 10:36 a.m. CEST on September 30, 2026, plus 0.14 percent against the EUR 22.20 prior close. A quoted 52-week range of EUR 16.34 to EUR 31.95 places the share below its yearly high, while the market capitalization stood at EUR 235.3 million on September 27, 2026.

The next quarterly and nine-month results are scheduled for November 12, 2026, according to Boerse Express. That date will test whether the Q2 margin recovery translated into the volume and cash generation needed for the full-year plan.